Neurotrope Inc (NASDAQ: NTRP) is a biotech that we covered a lot back in 2017 when the stock was trading like a rocket ship. Our subscribers were able to generate triple-digit returns on a consistent basis as the stock was a great trading vehicle. Since then, not much has happened wit NTRP and many long-term shareholders have been left disappointed and nursing losses. Have a look at the chart and see for yourself.
Now, we are taking another look at NTRP. After the recent Alzheimer’s treatment failure from Biogen Inc (NASDAQ: BIIB), we are looking at other Alzheimer treatment plays that could be takeover targets for BIIB and represent potential breakthrough’s in Alzheimer’s treatment. Neurotrope is certainly one of these biotechs.
First up, a little background info for those that are not familiar with NTRP.
Neurotrope describes itself as being at the forefront of developing a new approach to combating AD and other neurodegenerative diseases. The Company’s world-class science offers the potential to realize a paradigm shift to overcome one of today’s most challenging clinical problems — finding a way to slow or even prevent the progression of AD.
In addition to the Company’s Phase 2 trial of Bryostatin-1 in advanced AD, Neurotrope has also conducted preclinical studies of Bryostatin-1 as a potential treatment for rare diseases and brain injury, including Fragile X syndrome, multiple sclerosis, stroke, Niemann-Pick Type C disease, Rett syndrome, and traumatic brain injury. The FDA has granted Orphan Drug Designation to Neurotrope for Bryostatin-1 as a treatment for Fragile X. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety database that will further inform clinical trial designs.
NTRP Latest News
This month, Neurotrope announced that it initiated dosing in the final patient in the Company’s randomized, double-blind, placebo-controlled, confirmatory Phase 2 clinical trial of Bryostatin-1 in moderate to severe AD patients not on memantine. A total of 108 patients were enrolled into the study. Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope, said:
“Completion of enrollment in our confirmatory Phase 2 trial is an important step toward understanding the transformative potential of Bryostatin in moderate to severe Alzheimer’s disease, a neglected area of AD research with no effective treatment options. Bryostatin uses a novel, multi-modal mechanism of action which has demonstrated the ability to generate new, mature synaptic connections and prevent neuronal death in AD models. The promising data from our previous exploratory Phase 2 trial showed greater than baseline improvements in Severe Impairment Battery (SIB) scores for patients in the 20 µg Bryostatin-1 dose group, suggesting the potential to translate Bryostatin’s neurorestorative properties in the clinic.”
$28 million cash hoard
To see the company through the Phase 2 clinical trial, NTRP has over $28 million in cash. This is almost half the company’s current market cap. With this type of financial cushion, NTRP is an excellent risk/reward play at current levels.
Currently trading with a market cap of just $66 million, NTRP would be an easy buy for biotech giant Biogen with its $43 billion market cap. A lot will depend on the second half results of the latest Phase-2 study. If the results come in like Neurotrope expects them to, look out. NTRP will be off and running and Biogen won’t be the only company looking to buy Neurotrope.
We will be updating our subscribers as soon as we know more. For the latest updates on NTRP, sign up below!
Disclosure: We have no position in NTRP and have not been compensated for this article.